LEQEMBI® Intravenous Infusion (Lecanemab) Approved for

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO:

Related Keywords

Canada , Israel , South Korea , China , Cambridge , Cambridgeshire , United Kingdom , Australia , Massachusetts , United States , Switzerland , Japan , Tokyo , Tsukuba , Ibaraki , Great Britain , Japanese , Christophera Viehbacher , Haruo Naito , Exchange Commission , Youtube , Ad Cooperative Study , Ministry Of Health , Alzheimer Clinical Trial Consortium , Eisai Co Ltd , National Institutes Of Health , Twitter , Biogen Inc , Alzheimer Network Trials Unit , Washington University School Of Medicine , Facebook , Drug Administration , Tsukuba Research Laboratories , National Institute On , Linkedin , United Nations Sustainable Development Goals Sdgs , Intravenous Infusion , Clinical Dementia Rating Sum , Daily Living Scale , Mild Cognitive Impairment , Clinical Trials , New England Journal , Chief Executive Officer , Biogen Japan , Marketing Authorization , Dose Management , Antithrombotic Medication , Risk Factors , Intracerebral Hemorrhage , Innovative Licensing , Access Pathway , Clinical Trial Consortium , National Institute , National Institutes , Tau Nexgen , Dominantly Inherited , Washington University School , Corporate Concept , United Nations Sustainable Development Goals , Private Securities Litigation Reform Act ,